Science Matters: CD47 Pathway Links To CV Disease, New Drug Development Opportunities

29 Aug 2016

• By Mark Ratner

Initial research about inhibiting CD47 signaling on tumor cells has meant a focus on oncology drug development. New research shows that inhibiting this cell surface molecule could be used to treat atherosclerosis.

Since the publication in Cell seven years ago of research suggesting a treatment strategy around inhibiting CD47 signaling on tumor cells, the focus has been on the molecule’s role in oncology drug development. New research shows how inhibiting this cell surface molecule, which helps immune cells distinguish between self and non-self, could be used to treat atherosclerosis by restoring the ability of macrophages and neighboring cells to gobble up plaque debris.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble

18 Apr 2025

• By Alaric DeArment

The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.

Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten

15 Apr 2025

• By Alaric DeArment

BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

15 Apr 2025

• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.